agilon health inc. surged as investors reacted to strong value-based care performance; stocks have been trading up by 15.0 percent.
Click Here for a Millionaire's POV on Trading AGL
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For AGL Traders
- agilon health’s eight full‑risk ACO REACH entities generated $229M in 2024 gross savings at a 13.6% savings rate and 96% average quality score, managing around 121,000 Traditional Medicare lives.
- Since 2021, agilon’s REACH ACOs have produced $510M in gross savings, including $125M returned to the Medicare Trust Fund, with several ranked among top performers nationally.
- Wells Fargo more than doubled its price target on agilon health to $141 from $72 and reaffirmed an Overweight rating, pointing to improving Medicare Advantage and Exchange trends.
- agilon health scheduled its Q2 2026 earnings release and call but offered no early financials or guidance changes, keeping traders focused on the upcoming numbers.
- Menta’s hiring of a former agilon health Chief People Officer highlights AGL’s past success scaling its workforce and operations in value‑based care.
Live Update At 16:47:27 EDT: On Wednesday, August 05, 2026 agilon health inc. stock [NYSE: AGL] is trending up by 15.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
AGL has been trading like a momentum name, not a sleepy healthcare stock. On 2026/08/05, agilon health opened near $94.78 and ripped to an intraday high of $114.32 before closing at $107.85. That follows a big rebound from late July lows around $90–$92, telling traders there is strong dip buying in AGL whenever price washes out.
Intraday action shows AGL grinding higher through the session, with a violent push from the $98 area off the open up through $110+, then holding most of those gains into the close. That is classic accumulation behavior — higher highs, higher lows, and strong closes. For short‑term traders, AGL is acting like a crowded long with plenty of liquidity for day trades and swing trades.
More Breaking News
- BTG Stock Grinds Higher As Analysts Trim Targets
- HL Stock Climbs As Q2 Cash Flow Surges And Costs Drop
- UBER Stock Under Pressure As Legal, Deal, And Regulatory Risks Pile Up
- MARA Stock Slips As Price Target Cut And Insider Sale Hit Sentiment
Under the hood, agilon health is still in build‑out mode. Revenue runs around $5.93B annually with roughly 28% three‑year and 34% five‑year growth, but margins remain negative, and returns on equity and assets are deep in the red. AGL trades at roughly 0.27x sales and a rich 8.65x book value, signaling the market is paying up for future earnings power, not today’s profits. That combination — strong top‑line growth, weak current profitability, and aggressive valuation — keeps AGL a trader’s stock, not a value play.
Why Traders Are Watching AGL Right Now
AGL is back on screens because the story finally has teeth. Wells Fargo just more than doubled its price target on agilon health to $141 from $72 and stuck with an Overweight rating. When a major desk raises a target this aggressively, it tells traders sentiment has flipped from “prove it” to “this model works.” For AGL, that model is value‑based Medicare care at scale.
The latest data out of agilon health’s ACO REACH program backs that up. Across eight full‑risk ACOs, AGL generated $229M in gross savings in 2024, with a 13.6% savings rate and a stellar 96% average quality score while managing around 121,000 Traditional Medicare beneficiaries. Since 2021, those REACH entities have produced $510M in gross savings, including $125M kicked back to the Medicare Trust Fund. That is not a small pilot; it is a scaled platform that is saving real money and still delivering high quality.
For traders, this combination is powerful. AGL is showing the government and payors that it can run risk, cut costs, and keep outcomes strong. That is exactly the kind of story that supports premium multiples in healthcare services. It explains why Wells Fargo is comfortable rerating agilon health so sharply higher and why momentum traders are chasing every dip.
There is also a softer but important signal: Menta highlighted that its new CHRO previously helped agilon health scale rapidly. Talent gets poached from winning shops. That suggests AGL’s internal execution and growth history are strong enough to be a selling point in someone else’s press release. Layer on an upcoming Q2 2026 earnings call — the next catalyst where traders will be looking for REACH results to flow into margins and cash — and you have a clear near‑term event path around AGL.
Conclusion
For active traders, AGL sits at the crossroads of momentum, story, and execution. agilon health is putting up hard numbers in the ACO REACH program — $229M in 2024 gross savings, $510M since 2021, and a 96% quality score — that justify why Wall Street is paying attention. Wells Fargo’s move to a $141 target from $72 reinforces that large buyers now treat AGL as a high‑conviction healthcare growth name, even while reported margins remain in the red.
That does not mean the road is risk‑free. agilon health still runs negative profitability metrics, and Wells Fargo called Medicaid the key uncertainty. Any stumble on the upcoming Q2 2026 earnings call, or any sign that REACH success is not translating into cleaner earnings, can hit a richly valued stock hard. This is why AGL is a trader’s battlefield, not a sleepy long‑term hold.
For those studying the pattern, the plan is simple: track price action around support and resistance, watch volume on every breakout, and be ready to bail fast if the story cracks. As Tim Sykes loves to say, “The market doesn’t care about your opinion, only your discipline.” In that same spirit of rule‑based trading, As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.” With agilon health, discipline around news, levels, and risk is what separates the pros from the bagholders. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.